Page 8 - Nathalie Ponnier News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nathalie ponnier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nathalie Ponnier Today - Breaking & Trending Today

Vifor Pharma comments on media speculation

Vifor Pharma comments on media speculationST. GALLEN, Switzerland (BUSINESS WIRE) Regulatory News:AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRVifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on thes. ....

Vifor Pharma , Julien Vignot , Nathalie Ponnier , Swiss Stock Exchange , Vifor Pharma Group , Global Head Corporate Communications , Swiss Exchange , Fresenius Medical Care , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , Investor Relations ,

Vifor Pharma Group: CSL Limited announces tender offer to acquire Vifor Pharma Ltd

Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent to CHF167 per share1 ....

Vifor Pharma , Jacques Theurillat , Julien Vignot , Nathalie Ponnier , Board Of Directors Vifor Pharma Group , Swiss Stock Exchange , Global Head Corporate Communications , Swiss Exchange , Australian Securities Exchange , Shareholders Of Vifor Pharma Ltd , Vifor Pharma Ltd , Centerview Partners United Kingdom , Vifor Pharma Group , Dynamics Group , Fresenius Medical Care , Directors Vifor Pharma Group , Fairness Opinion , Vifor Pharma Board , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , Head Corporate Communications , Investor Relations ,

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

. 10, 2021 06:00 UTCVifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury ST. GALLEN, Switzerland & UNIONDALE, N.Y. (BUSINESS WIRE) Regulatory News:This press release features multimedia. View the full release here: https://. ....

John Neylan , Vifor Pharma , Julien Vignot , Klaus Henning Jensen , Nathalie Ponnier , Exchange Commission On , Swiss Stock Exchange , Global Head Corporate Communications , Angion Biomedica Corp , Swiss Exchange , Exchange Commission , Vifor Pharma Group , Fresenius Medical Care , Angion Biomedica , Estimated Glomerular Filtration Rate , Chief Medical Officer , Chief Medical , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , Greater China , Guard Against Renal Damage , Private Securities Litigation Reform Act , Quarterly Report , Investor Relations ,

Vifor Pharma comments on media speculation

Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions. ....

Vifor Pharma , Julien Vignot , Nathalie Ponnier , Swiss Stock Exchange , Vifor Pharma Group , Global Head Corporate Communications , Swiss Exchange , Fresenius Medical Care , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , Media Contact , Head Corporate Communications , Investor Relations , Vifor Pharma , Ad Hoc Announcement , Regulatory News , Iron Deficiency , Cardio Renal Therapies , Fresenius Medical Care ,

First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease

Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult patients with sickle cell disease. ....

United States , United Kingdom , Vifor Pharma , Julien Vignot , Klaus Henning Jensen , Nathalie Ponnier , Swiss Stock Exchange , Drug Administration , Global Head Corporate Communications , Swiss Exchange , Vifor Pharma Group , European Medicines Agency , Fresenius Medical Care , Chief Medical Officer , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , Media Contact , Head Corporate Communications , Investor Relations , Vifor Pharma Group , Sickle Cell Disease , Ral Ferroportin Inhibitor , Red Blood Cells , Rare Blood Disorder , Treatment Options , Hase Iia Clinical Trial ,